Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free TRDA Stock Alerts

Entrada Therapeutics (TRDA) Financials

Entrada Therapeutics logo
$6.46 +0.15 (+2.38%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$6.45 -0.01 (-0.15%)
As of 06/12/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Entrada Therapeutics

Annual Income Statements for Entrada Therapeutics

This table shows Entrada Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -97 -6.69 66
Consolidated Net Income / (Loss)		 -95 -6.69 66
Net Income / (Loss) Continuing Operations		 -95 -6.69 66
Total Pre-Tax Income 		-95 12 66
Total Operating Income		 -97 -3.16 47
Total Gross Profit		 0.00 129 211
Total Revenue		 0.00 129 211
Operating Revenue		 0.00 129 211
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 97 132 164
Selling, General & Admin Expense		 31 32 38
Research & Development Expense		 67 100 125
Total Other Income / (Expense), net		 2.63 15 19
Other Income / (Expense), net		 2.63 15 19
Income Tax Expense		 0.00 19 0.86
Basic Earnings per Share		 ($3.02) ($0.20) $1.76
Weighted Average Basic Shares Outstanding		 31.29M 33.05M 37.31M
Diluted Earnings per Share		 ($3.02) ($0.20) $1.68
Weighted Average Diluted Shares Outstanding		 31.29M 33.05M 39.00M
Weighted Average Basic & Diluted Shares Outstanding		 33.08M 33.60M 37.59M

Quarterly Income Statements for Entrada Therapeutics

This table shows Entrada Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -25 -27 -6.67 -26 36 -10 23 55 -14 1.21
Consolidated Net Income / (Loss)		 -25 -25 -6.67 -26 35 -9.54 23 55 -14 1.13
Net Income / (Loss) Continuing Operations		 -25 -25 -6.67 -26 35 -9.54 23 55 -14 1.13
Total Pre-Tax Income 		-25 -25 -3.12 -12 18 9.20 25 58 -16 -0.74
Total Operating Income		 -26 -26 -5.78 -16 14 4.91 21 53 -22 -5.87
Total Gross Profit		 0.00 - 25 18 44 42 59 95 20 37
Total Revenue		 0.00 - 25 18 44 42 59 95 20 37
Operating Revenue		 0.00 - 25 18 44 42 59 95 20 37
Total Operating Expenses		 26 26 31 34 30 37 38 41 41 43
Selling, General & Admin Expense		 6.98 9.89 7.94 8.17 7.53 8.65 9.40 9.24 9.97 9.86
Research & Development Expense		 19 16 23 26 22 28 29 32 31 33
Total Other Income / (Expense), net		 0.80 0.95 2.66 4.22 4.05 4.29 4.21 4.37 5.77 5.13
Other Income / (Expense), net		 0.80 0.95 2.66 - 4.05 - 4.21 4.37 5.77 5.13
Income Tax Expense		 0.00 - 3.55 14 -17 19 1.83 2.76 -1.86 -1.87
Basic Earnings per Share		 ($0.80) ($0.79) ($0.21) ($0.78) $1.07 ($0.28) $0.70 $1.61 ($0.35) ($0.20)
Weighted Average Basic Shares Outstanding		 31.30M 31.29M 32.37M 33.16M 33.28M 33.05M 33.50M 34.18M 40.63M 37.31M
Diluted Earnings per Share		 ($0.80) ($0.79) ($0.21) ($0.78) $1.02 ($0.23) $0.68 $1.55 ($0.35) ($0.20)
Weighted Average Diluted Shares Outstanding		 31.30M 31.29M 32.37M 33.16M 34.78M 33.05M 34.79M 35.51M 40.63M 39.00M
Weighted Average Basic & Diluted Shares Outstanding		 31.41M 33.08M 33.20M 33.27M 33.37M 33.60M 33.76M 37.20M 37.42M 37.59M

Annual Cash Flow Statements for Entrada Therapeutics

This table details how cash moves in and out of Entrada Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -242 22 34
Net Cash From Operating Activities		 -94 140 -42
Net Cash From Continuing Operating Activities		 -94 140 -42
Net Income / (Loss) Continuing Operations		 -95 -6.69 66
Consolidated Net Income / (Loss)		 -95 -6.69 66
Depreciation Expense		 1.90 2.84 3.77
Amortization Expense		 0.15 -5.78 -10
Non-Cash Adjustments To Reconcile Net Income		 18 13 18
Changes in Operating Assets and Liabilities, net		 -19 136 -119
Net Cash From Investing Activities		 -149 -138 -28
Net Cash From Continuing Investing Activities		 -149 -138 -28
Purchase of Property, Plant & Equipment		 -2.89 -5.61 -3.16
Purchase of Investments		 -222 -407 -438
Sale and/or Maturity of Investments		 76 274 413
Net Cash From Financing Activities		 0.48 21 103
Net Cash From Continuing Financing Activities		 0.48 21 103
Issuance of Common Equity		 0.20 21 103
Cash Income Taxes Paid		 0.00 15 4.62

Quarterly Cash Flow Statements for Entrada Therapeutics

This table details how cash moves in and out of Entrada Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -38 -8.15 182 -148 -28 16 0.83 117 -107 23
Net Cash From Operating Activities		 -27 -27 203 -35 -24 -4.01 -26 40 -24 -32
Net Cash From Continuing Operating Activities		 -27 -27 203 -35 -24 -4.01 -26 40 -24 -32
Net Income / (Loss) Continuing Operations		 -25 -25 -6.67 -26 35 -9.54 23 55 -14 1.13
Consolidated Net Income / (Loss)		 -25 -25 -6.67 -26 35 -9.54 23 55 -14 1.13
Depreciation Expense		 0.52 0.53 0.54 0.73 0.83 0.74 0.93 0.91 0.94 0.99
Amortization Expense		 -0.03 -0.10 -0.24 -1.69 -1.85 -2.00 -2.04 -2.26 -3.21 -2.51
Non-Cash Adjustments To Reconcile Net Income		 2.71 11 2.76 3.12 3.40 3.84 3.73 4.62 4.86 4.70
Changes in Operating Assets and Liabilities, net		 -5.54 -14 207 -11 -62 2.95 -52 -18 -13 -36
Net Cash From Investing Activities		 -10 19 -40 -113 -3.74 19 26 -24 -83 53
Net Cash From Continuing Investing Activities		 -10 19 -40 -113 -3.74 19 26 -24 -83 53
Purchase of Property, Plant & Equipment		 -0.81 -0.71 -1.67 -1.52 -1.45 -0.98 -0.84 -1.05 -0.64 -0.64
Purchase of Investments		 -39 - -102 -140 -77 -89 -97 -111 -166 -64
Sale and/or Maturity of Investments		 30 20 63 28 75 109 124 87 83 118
Net Cash From Financing Activities		 0.06 0.36 20 0.44 0.37 0.69 0.21 101 -0.01 1.40
Net Cash From Continuing Financing Activities		 0.06 0.36 20 0.44 0.37 0.69 0.21 101 -0.01 1.40
Issuance of Common Equity		 - 0.20 19 0.19 - 1.44 0.00 100 -0.39 3.09

Annual Balance Sheets for Entrada Therapeutics

This table presents Entrada Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 252 469 526
Total Current Assets		 210 370 440
Cash & Equivalents		 45 68 101
Short-Term Investments		 144 284 319
Prepaid Expenses		 21 12 16
Other Current Assets		 0.00 5.88 3.68
Plant, Property, & Equipment, net		 7.68 11 11
Total Noncurrent Assets		 35 88 75
Other Noncurrent Operating Assets		 35 88 75
Total Liabilities & Shareholders' Equity		 252 469 526
Total Liabilities		 40 227 98
Total Current Liabilities		 22 159 39
Short-Term Debt		 8.41 - 7.56
Accounts Payable		 5.99 3.28 4.26
Accrued Expenses		 7.58 11 13
Current Deferred Revenue		 0.00 132 14
Current Deferred & Payable Income Tax Liabilities		 0.00 4.02 0.67
Total Noncurrent Liabilities		 18 68 58
Noncurrent Deferred Revenue		 0.00 7.72 6.51
Other Noncurrent Operating Liabilities		 18 60 52
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 213 242 429
Total Preferred & Common Equity		 213 242 429
Total Common Equity		 213 242 429
Common Stock		 403 437 558
Retained Earnings		 -188 -195 -129
Accumulated Other Comprehensive Income / (Loss)		 -2.06 0.20 -0.04

Quarterly Balance Sheets for Entrada Therapeutics

This table presents Entrada Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 274 476 494 485 511 582 555
Total Current Assets		 235 434 390 383 414 490 465
Cash & Equivalents		 53 228 80 52 68 185 78
Short-Term Investments		 162 184 297 302 259 284 371
Prepaid Expenses		 19 16 9.66 24 9.24 12 13
Other Current Assets		 - 6.30 3.74 5.03 78 7.67 2.60
Plant, Property, & Equipment, net		 7.44 9.39 11 11 11 11 11
Total Noncurrent Assets		 32 32 93 91 86 81 78
Other Noncurrent Operating Assets		 32 32 93 91 86 81 78
Total Liabilities & Shareholders' Equity		 274 476 494 485 511 582 555
Total Liabilities		 41 246 287 238 241 152 132
Total Current Liabilities		 22 148 126 165 174 86 71
Short-Term Debt		 - - - - - - 7.74
Accounts Payable		 1.34 6.47 2.42 0.75 2.53 1.64 1.29
Accrued Expenses		 12 12 7.11 9.60 8.79 11 13
Current Deferred Revenue		 - 122 102 148 148 60 46
Current Deferred & Payable Income Tax Liabilities		 - - 7.36 - 5.86 4.11 2.25
Total Noncurrent Liabilities		 20 98 161 73 68 66 62
Capital Lease Obligations		 - - - - - - 54
Noncurrent Deferred Revenue		 0.00 89 96 11 9.41 10 7.96
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 233 230 207 247 269 430 422
Total Preferred & Common Equity		 233 230 207 247 269 430 422
Total Common Equity		 233 230 207 247 269 430 422
Common Stock		 400 425 429 433 441 547 552
Retained Earnings		 -164 -195 -221 -185 -171 -116 -130
Accumulated Other Comprehensive Income / (Loss)		 -2.75 -0.64 -1.01 -0.50 -0.25 -0.33 0.97

Annual Metrics And Ratios for Entrada Therapeutics

This table displays calculated financial ratios and metrics derived from Entrada Therapeutics' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 63.38%
EBITDA Growth		 -84.99% 109.85% 560.67%
EBIT Growth		 -84.95% 112.74% 451.47%
NOPAT Growth		 -90.21% 102.58% 2,546.62%
Net Income Growth		 -84.95% 92.93% 1,081.69%
EPS Growth		 62.99% 93.38% 940.00%
Operating Cash Flow Growth		 -84.39% 249.07% -129.73%
Free Cash Flow Firm Growth		 -118.97% 254.97% -155.32%
Invested Capital Growth		 321.32% -439.89% 114.82%
Revenue Q/Q Growth		 0.00% 48.01% -2.07%
EBITDA Q/Q Growth		 -7.08% 126.13% 16.32%
EBIT Q/Q Growth		 -6.99% 135.83% 15.06%
NOPAT Q/Q Growth		 -7.90% 107.44% 11.68%
Net Income Q/Q Growth		 -6.99% 69.29% 19.43%
EPS Q/Q Growth		 -122.17% 73.68% 1.82%
Operating Cash Flow Q/Q Growth		 -7.77% 19.99% -197.58%
Free Cash Flow Firm Q/Q Growth		 0.00% 42.17% 20.38%
Invested Capital Q/Q Growth		 82.73% -2.52% -52.82%
Profitability Metrics		 - - -
Gross Margin		 0.00% 100.00% 100.00%
EBITDA Margin		 0.00% 7.07% 28.58%
Operating Margin		 0.00% -2.45% 22.30%
EBIT Margin		 0.00% 9.34% 31.54%
Profit (Net Income) Margin		 0.00% -5.18% 31.13%
Tax Burden Percent		 100.00% -55.45% 98.71%
Interest Burden Percent		 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 155.45% 1.29%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -37.01% -2.94% 19.56%
Cash Return on Invested Capital (CROIC)		 -464.48% 0.00% -489.22%
Operating Return on Assets (OROA)		 0.00% 3.34% 13.36%
Return on Assets (ROA)		 0.00% -1.85% 13.18%
Return on Common Equity (ROCE)		 -37.01% -2.94% 19.56%
Return on Equity Simple (ROE_SIMPLE)		 -44.51% -2.76% 15.31%
Net Operating Profit after Tax (NOPAT)		 -68 1.75 46
NOPAT Margin		 0.00% 1.36% 22.02%
Net Nonoperating Expense Percent (NNEP)		 -11.26% -3.17% 5.03%
Return On Investment Capital (ROIC_SIMPLE)		 - 0.72% 10.64%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 25.03% 18.25%
R&D to Revenue		 0.00% 77.42% 59.45%
Operating Expenses to Revenue		 0.00% 102.45% 77.70%
Earnings before Interest and Taxes (EBIT)		 -95 12 66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -93 9.12 60
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 2.00 2.08 1.51
Price to Tangible Book Value (P/TBV)		 2.00 2.08 1.51
Price to Revenue (P/Rev)		 0.00 3.90 3.07
Price to Earnings (P/E)		 0.00 0.00 9.86
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 10.14%
Enterprise Value to Invested Capital (EV/IC)		 7.58 0.00 14.44
Enterprise Value to Revenue (EV/Rev)		 0.00 1.17 1.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 16.62 3.89
Enterprise Value to EBIT (EV/EBIT)		 0.00 12.57 3.53
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 86.44 5.05
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 1.08 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 1.06 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.04 0.00 0.02
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.92 -1.17 -1.14
Leverage Ratio		 1.09 1.59 1.48
Compound Leverage Factor		 1.09 1.59 1.48
Debt to Total Capital		 3.80% 0.00% 1.73%
Short-Term Debt to Total Capital		 3.80% 0.00% 1.73%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 96.20% 100.00% 98.27%
Debt to EBITDA		 -0.09 0.00 0.13
Net Debt to EBITDA		 1.95 0.00 -6.85
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 -0.12 0.00 0.16
Net Debt to NOPAT		 2.65 0.00 -8.89
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 5.06 1.65 5.36
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 9.55 2.33 11.15
Quick Ratio		 8.59 2.22 10.64
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -93 144 -79
Operating Cash Flow to CapEx		 -3,248.56% 2,490.26% -1,315.93%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.36 0.42
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 13.67 19.06
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 32 -110 16
Invested Capital Turnover		 0.00 -3.34 -4.52
Increase / (Decrease) in Invested Capital		 25 -142 126
Enterprise Value (EV)		 244 152 235
Market Capitalization		 425 504 647
Book Value per Share		 $6.77 $7.26 $11.46
Tangible Book Value per Share		 $6.77 $7.26 $11.46
Total Capital		 221 242 436
Total Debt		 8.41 0.00 7.56
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -180 -352 -412
Capital Expenditures (CapEx)		 2.89 5.61 3.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 7.60 -141 -12
Debt-free Net Working Capital (DFNWC)		 196 211 408
Net Working Capital (NWC)		 188 211 401
Net Nonoperating Expense (NNE)		 27 8.44 -19
Net Nonoperating Obligations (NNO)		 -180 -352 -412
Total Depreciation and Amortization (D&A)		 2.05 -2.94 -6.25
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -109.29% -5.64%
Debt-free Net Working Capital to Revenue		 0.00% 163.53% 193.62%
Net Working Capital to Revenue		 0.00% 163.53% 190.03%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($3.02) ($0.20) $1.76
Adjusted Weighted Average Basic Shares Outstanding		 31.29M 33.05M 37.31M
Adjusted Diluted Earnings per Share		 ($3.02) ($0.20) $1.68
Adjusted Weighted Average Diluted Shares Outstanding		 31.29M 33.05M 39.00M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 33.08M 33.60M 37.59M
Normalized Net Operating Profit after Tax (NOPAT)		 -68 -2.21 46
Normalized NOPAT Margin		 0.00% -1.72% 22.02%
Pre Tax Income Margin		 0.00% 9.34% 31.54%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Entrada Therapeutics

This table displays calculated financial ratios and metrics derived from Entrada Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 134.05% 421.16% -55.25% -10.63%
EBITDA Growth		 -74.50% -33.87% 86.66% 23.53% 169.14% 115.05% 959.31% 426.99% -206.59% -161.89%
EBIT Growth		 -74.20% -33.51% 85.59% 29.68% 171.86% 119.92% 910.98% 454.56% -187.98% -115.07%
NOPAT Growth		 -80.56% -38.56% 73.91% 30.88% 251.52% 71.57% 584.10% 545.89% -155.11% 19.32%
Net Income Growth		 -74.20% -33.51% 69.20% -11.86% 241.07% 61.25% 452.05% 312.25% -139.57% 111.85%
EPS Growth		 91.82% -104.98% 69.57% -5.41% 227.50% 70.89% 423.81% 298.72% -134.31% 13.04%
Operating Cash Flow Growth		 -95.25% -32.92% 1,068.98% -94.85% 10.88% 85.30% -112.55% 213.51% 0.92% -687.57%
Free Cash Flow Firm Growth		 -158.80% 0.00% 760.33% 701.78% 559.75% 421.81% -154.52% -146.51% -202.91% -195.02%
Invested Capital Growth		 547.40% 321.32% -1,449.39% -1,541.50% -705.82% -439.89% 68.11% 76.56% 132.19% 114.82%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -28.07% 140.70% -4.31% 41.27% 60.17% -79.33% 91.10%
EBITDA Q/Q Growth		 -9.22% 1.81% 88.35% -512.27% 198.75% -78.63% 565.13% 132.98% -132.19% 87.59%
EBIT Q/Q Growth		 -8.45% 2.02% 87.32% -421.90% 210.82% -72.85% 416.35% 128.17% -127.50% 95.35%
NOPAT Q/Q Growth		 -9.98% 1.38% 77.40% -181.99% 341.10% -118.50% 484.80% 159.73% -129.80% 72.91%
Net Income Q/Q Growth		 -8.45% 2.02% 72.90% -288.49% 236.77% -126.91% 346.19% 134.21% -125.50% 108.06%
EPS Q/Q Growth		 -8.11% 1.25% 73.42% -271.43% 230.77% -122.55% 395.65% 127.94% -122.58% 42.86%
Operating Cash Flow Q/Q Growth		 -52.60% 0.65% 844.94% -117.25% 30.20% 83.62% -535.91% 256.09% -160.92% -30.24%
Free Cash Flow Firm Q/Q Growth		 -16.91% -28.49% 550.51% -11.08% -10.68% -10.06% -176.32% 24.14% -97.63% 16.96%
Invested Capital Q/Q Growth		 49.75% 82.73% -664.44% 6.67% 37.06% -2.52% 47.04% 31.40% 186.43% -52.82%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -11.16% -94.99% 38.97% 8.70% 40.97% 59.60% -92.84% -6.03%
Operating Margin		 0.00% 0.00% -22.88% -89.70% 32.04% 11.72% 35.71% 56.42% -110.67% -15.69%
EBIT Margin		 0.00% 0.00% -12.36% -89.70% 41.30% 11.72% 42.84% 61.03% -81.21% -1.98%
Profit (Net Income) Margin		 0.00% 0.00% -26.42% -142.70% 81.08% -22.81% 39.74% 58.11% -71.70% 3.02%
Tax Burden Percent		 100.00% 100.00% 213.70% 214.62% 196.32% -103.77% 92.77% 95.23% 88.30% -153.04%
Interest Burden Percent		 100.00% 100.00% 100.00% 74.12% 100.00% 187.50% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% -96.32% 203.77% 7.23% 4.77% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -49.39% -37.01% -31.41% -35.58% -9.07% -2.94% 9.41% 32.80% 16.43% 19.56%
Cash Return on Invested Capital (CROIC)		 0.00% -464.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -289.92% -489.22%
Operating Return on Assets (OROA)		 0.00% 0.00% -0.79% -9.86% 9.48% 4.19% 14.15% 27.16% -33.62% -0.84%
Return on Assets (ROA)		 0.00% 0.00% -1.68% -15.69% 18.61% -8.16% 13.12% 25.86% -29.69% 1.28%
Return on Common Equity (ROCE)		 -22.15% -37.01% -31.41% -35.58% -9.07% -2.94% 9.41% 32.80% 16.43% 19.56%
Return on Equity Simple (ROE_SIMPLE)		 -37.92% 0.00% -34.68% -39.81% -8.83% 0.00% 8.72% 24.29% 13.01% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -18 -4.05 -11 28 -5.09 20 51 -15 -4.11
NOPAT Margin		 0.00% 0.00% -16.02% -62.79% 62.90% -12.16% 33.13% 53.72% -77.47% -10.98%
Net Nonoperating Expense Percent (NNEP)		 -4.13% -2.85% -0.78% -4.68% 2.79% -1.67% 1.06% 0.98% 0.30% 1.37%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -2.10% - - - -0.94%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 31.43% 44.96% 17.22% 20.67% 15.90% 9.75% 50.95% 26.36%
R&D to Revenue		 0.00% 0.00% 91.46% 144.74% 50.74% 67.60% 48.39% 33.83% 159.72% 89.33%
Operating Expenses to Revenue		 0.00% 0.00% 122.88% 189.70% 67.96% 88.28% 64.29% 43.58% 210.67% 115.69%
Earnings before Interest and Taxes (EBIT)		 -25 -25 -3.12 -16 18 4.91 25 58 -16 -0.74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -24 -2.82 -17 17 3.64 24 56 -18 -2.25
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.12 2.00 2.09 2.43 0.00 2.08 1.77 1.12 1.41 1.51
Price to Tangible Book Value (P/TBV)		 2.12 2.00 2.09 2.43 0.00 2.08 1.77 1.12 1.41 1.51
Price to Revenue (P/Rev)		 0.00 0.00 18.99 11.57 0.00 3.90 2.92 2.01 2.76 3.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 18.50 4.51 10.50 9.86
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.41% 22.16% 9.52% 10.14%
Enterprise Value to Invested Capital (EV/IC)		 15.80 7.58 0.00 0.00 0.00 0.00 0.00 0.00 6.00 14.44
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 2.69 2.90 0.00 1.17 0.91 0.05 0.96 1.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 16.62 4.11 0.13 3.99 3.89
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 12.57 3.67 0.12 3.57 3.53
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 86.44 10.81 0.13 4.97 5.05
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.52 1.11 0.00 1.08 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.49 0.97 0.00 1.06 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.02
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.13 0.00
Financial Leverage		 -0.94 -0.92 -1.33 -1.34 -1.19 -1.17 -1.48 -1.33 -1.11 -1.14
Leverage Ratio		 1.14 1.09 1.56 1.71 1.58 1.59 1.98 1.69 1.55 1.48
Compound Leverage Factor		 1.14 1.09 1.56 1.26 1.58 2.97 1.98 1.69 1.55 1.48
Debt to Total Capital		 0.00% 3.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.67% 1.73%
Short-Term Debt to Total Capital		 0.00% 3.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.60% 1.73%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11.07% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 96.20% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 87.33% 98.27%
Debt to EBITDA		 0.00 -0.09 0.00 0.00 0.00 0.00 0.00 0.00 1.18 0.13
Net Debt to EBITDA		 0.00 1.95 0.00 0.00 0.00 0.00 0.00 0.00 -7.49 -6.85
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.03 0.00
Debt to NOPAT		 0.00 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 1.48 0.16
Net Debt to NOPAT		 0.00 2.65 0.00 0.00 0.00 0.00 0.00 0.00 -9.34 -8.89
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.29 0.00
Altman Z-Score		 6.99 5.98 1.35 1.05 0.00 1.60 1.76 3.19 3.52 4.94
Noncontrolling Interest Sharing Ratio		 55.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 10.89 9.55 2.94 3.10 2.32 2.33 2.38 5.70 6.59 11.15
Quick Ratio		 10.00 8.59 2.79 2.99 2.14 2.22 1.88 5.47 6.36 10.64
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -33 -42 191 170 152 137 -104 -79 -156 -130
Operating Cash Flow to CapEx		 -3,392.84% -3,856.50% 12,194.18% -2,305.58% -1,691.44% -411.17% -3,045.23% 3,808.13% -3,797.50% -4,977.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.06 0.11 0.23 0.36 0.33 0.45 0.41 0.42
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 3.05 4.62 9.43 13.67 15.97 21.41 19.72 19.06
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 18 32 -182 -170 -107 -110 -58 -40 34 16
Invested Capital Turnover		 0.00 0.00 -0.30 -0.55 -1.95 -3.34 -1.36 -2.28 -5.94 -4.52
Increase / (Decrease) in Invested Capital		 15 25 -196 -182 -125 -142 124 130 141 126
Enterprise Value (EV)		 279 244 68 126 0.00 152 149 11 206 235
Market Capitalization		 494 425 480 503 0.00 504 476 481 594 647
Book Value per Share		 $7.43 $6.77 $6.94 $6.23 $7.41 $7.26 $8.02 $12.74 $11.36 $11.46
Tangible Book Value per Share		 $7.43 $6.77 $6.94 $6.23 $7.41 $7.26 $8.02 $12.74 $11.36 $11.46
Total Capital		 233 221 230 207 247 242 269 430 484 436
Total Debt		 0.00 8.41 0.00 0.00 0.00 0.00 0.00 0.00 61 7.56
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 54 0.00
Net Debt		 -216 -180 -412 -377 -354 -352 -327 -470 -388 -412
Capital Expenditures (CapEx)		 0.81 0.71 1.67 1.52 1.45 0.98 0.84 1.05 0.64 0.64
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.39 7.60 -125 -113 -136 -141 -87 -66 -47 -12
Debt-free Net Working Capital (DFNWC)		 213 196 287 264 218 211 240 404 402 408
Net Working Capital (NWC)		 213 188 287 264 218 211 240 404 395 401
Net Nonoperating Expense (NNE)		 6.98 6.72 2.63 15 -7.95 4.45 -3.91 -4.16 -1.13 -5.24
Net Nonoperating Obligations (NNO)		 -216 -180 -412 -377 -354 -352 -327 -470 -388 -412
Total Depreciation and Amortization (D&A)		 0.48 0.42 0.30 -0.96 -1.02 -1.26 -1.10 -1.35 -2.28 -1.52
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -495.21% -259.12% -155.99% -109.29% -53.53% -27.58% -21.78% -5.64%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,134.37% 608.46% 249.65% 163.53% 147.50% 168.64% 186.99% 193.62%
Net Working Capital to Revenue		 0.00% 0.00% 1,134.37% 608.46% 249.65% 163.53% 147.50% 168.64% 183.40% 190.03%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.80) ($0.79) ($0.21) ($0.78) $1.07 ($0.28) $0.70 $1.61 ($0.35) ($0.20)
Adjusted Weighted Average Basic Shares Outstanding		 31.30M 31.29M 32.37M 33.16M 33.28M 33.05M 33.50M 34.18M 40.63M 37.31M
Adjusted Diluted Earnings per Share		 ($0.80) ($0.79) ($0.21) ($0.78) $1.02 ($0.23) $0.68 $1.55 ($0.35) ($0.20)
Adjusted Weighted Average Diluted Shares Outstanding		 31.30M 31.29M 32.37M 33.16M 34.78M 33.05M 34.79M 35.51M 40.63M 39.00M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 31.41M 33.08M 33.20M 33.27M 33.37M 33.60M 33.76M 37.20M 37.42M 37.59M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -18 -4.05 -11 9.81 3.43 20 51 -15 -4.11
Normalized NOPAT Margin		 0.00% 0.00% -16.02% -62.79% 22.43% 8.20% 33.13% 53.72% -77.47% -10.98%
Pre Tax Income Margin		 0.00% 0.00% -12.36% -66.49% 41.30% 21.98% 42.84% 61.03% -81.21% -1.98%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Entrada Therapeutics (NASDAQ: TRDA) showed a mixed but overall improving financial picture in 2024, with strong revenue growth and a return to profitability in Q4, but continued weakness in operating cash flow and a still-heavy dependence on non-operating income and investment activity.

Revenue trends were impressive. Quarterly revenue rose from $25.3 million in Q1 2023 to $59.1 million in Q1 2024, then remained elevated at $94.7 million in Q2 2024 before easing to $19.6 million in Q3 and $37.4 million in Q4. Even with quarter-to-quarter volatility, the company generated materially higher sales in 2024 than in 2023.

Profitability improved sharply by the end of 2024. Q4 2024 net income was $1.1 million versus a net loss of $14.0 million in Q3 2024 and a loss of $9.5 million in Q4 2023. The swing was driven partly by lower operating losses and strong other income.

Operating expenses remain the main challenge. In Q4 2024, Entrada generated $37.4 million of revenue but spent $43.3 million on operating expenses, producing an operating loss of $5.9 million. R&D alone was $33.4 million, showing the business is still investing aggressively in development rather than operating at scale.

Cash generation is still a concern. Q4 2024 operating cash flow was a negative $31.6 million, following negative $24.3 million in Q3 2024 and positive $39.8 million in Q2 2024. For a biotech-style company, this means profitability on paper does not yet translate into consistent cash from operations.

The balance sheet remains a key strength. As of Q3 2024, Entrada held $78.0 million in cash and equivalents and $371.3 million in short-term investments, for roughly $449 million in liquid resources. Total current assets were $465.3 million against total liabilities of $132.1 million, leaving the company with a solid liquidity cushion.

Liquidity has declined from earlier in the year. Cash and equivalents fell from $185.3 million in Q2 2024 to $78.0 million in Q3 2024, reflecting the company’s operating burn and investment activity. That said, the short-term investment balance remains substantial.

  • Revenue growth accelerated meaningfully in 2024, with quarterly sales well above 2023 levels.
  • Q4 2024 returned to net profitability, with $1.1 million in net income.
  • Large investment portfolio supports liquidity, with more than $371 million in short-term investments at Q3 2024.
  • Total equity remained strong at $422.4 million in Q3 2024.
  • Results remain lumpy quarter to quarter, with revenue and earnings swinging materially.
  • Other income contributed heavily to profits in multiple quarters, so core operating performance is still not fully self-sustaining.
  • Operating cash flow stayed negative in Q4 2024 at $31.6 million.
  • Operating losses persisted in Q4 2024 despite revenue growth, with a $5.9 million operating loss.
  • R&D spending remains very high and continues to pressure margins and cash flow.
  • Cash declined sharply from mid-2024 levels, signaling continued burn from operations and investments.

Bottom line: Entrada Therapeutics ended 2024 with better top-line momentum and a return to profitability, but the company is still spending heavily and burning cash. Investors should view the name as financially well-capitalized for now, yet still dependent on continued clinical and operational progress to support a more durable earnings profile.

06/13/26 04:39 PM ETAI Generated. May Contain Errors.

Entrada Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Entrada Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Entrada Therapeutics' net income appears to be on a downward trend, with a most recent value of $65.63 million in 2024, falling from -$94.62 million in 2022. The previous period was -$6.69 million in 2023. See where experts think Entrada Therapeutics is headed by visiting Entrada Therapeutics' forecast page.

Entrada Therapeutics' total operating income in 2024 was $47.01 million, based on the following breakdown:
  • Total Gross Profit: $210.78 million
  • Total Operating Expenses: $163.77 million

Over the last 2 years, Entrada Therapeutics' total revenue changed from $0.00 in 2022 to $210.78 million in 2024, a change of 21,078,200,000.0%.

Entrada Therapeutics' total liabilities were at $97.64 million at the end of 2024, a 57.0% decrease from 2023, and a 147.2% increase since 2022.

In the past 2 years, Entrada Therapeutics' cash and equivalents has ranged from $45.16 million in 2022 to $101.21 million in 2024, and is currently $101.21 million as of their latest financial filing in 2024.

Over the last 2 years, Entrada Therapeutics' book value per share changed from 6.77 in 2022 to 11.46 in 2024, a change of 69.3%.


Related Companies

Financial statements for NASDAQ:TRDA last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...
Behind the Markets | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel